Scientist from EU-supported institute makes important cancer gene discovery
A young scientist from a Czech research institute established in 2011 with European Union funding with the aim of becoming a leading European centre of science has made an important genetic discovery which could lead to more effective treatment for some forms of hereditary breast and ovarian cancer.
Research carried out by Michal Zimmermann, a postgraduate student of Dr. Ctirad Hofr from the Central European Institute of Technology (CEITEC), has revealed that the loss of the gene Rif1, or a mutation of it which makes it inactive, is able to make cancer cells more resistant to standard treatment for these two cancers by halting and reversing the effects of chemotherapy.
Situated in Brno, Czech Republic, and supported by funding from the EU’s Regional Development Fund, CEITEC is a centre of scientific excellence in the fields of life sciences and advanced materials and technologies.
Michael Zimmermann made his discovery while working as part of his postgraduate studies at the prestigious Rockefeller University in New York, and published his research in January 2013 in the Journal Science.
About CEITEC : High ambitions for new European Centre of Excellence